StockMacro
Menu

Kyverna Therapeutics

$4.26 -51% in 6 monthsMarket cap $269.3M

KYTX on XNAS, Health Care, Kyverna Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 43% in a year as the net loss reached $157.8M and cash stands at $170.6M.

  • BadShort interest at 14% of shares, down 4.7% on prior report
  • GoodInstitutional holders rose to 127 from 119 last quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
172
Website
kyvernatx.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $41.9M.
Quarter to 31 Mar 2023: revenue –, net income -$11.1MQuarter to 30 Jun 2023: revenue –, net income -$13.1MQuarter to 30 Sep 2023: revenue –, net income -$15.5MQuarter to 31 Dec 2023: revenue –, net income -$20.7MQuarter to 31 Mar 2024: revenue –, net income -$26.7MQuarter to 30 Jun 2024: revenue –, net income -$28.8MQuarter to 30 Sep 2024: revenue –, net income -$34.5MQuarter to 31 Dec 2024: revenue –, net income -$37.5MQuarter to 31 Mar 2025: revenue –, net income -$44.6MQuarter to 30 Jun 2025: revenue –, net income -$42.1MQuarter to 30 Sep 2025: revenue –, net income -$36.8MQuarter to 31 Dec 2025: revenue –, net income -$37.8MQuarter to 31 Mar 2026: revenue –, net income -$39.7MQuarter to 30 Jun 2026: revenue –, net income -$38.3MQuarter to 30 Sep 2026: revenue –, net income -$41.9M
31 Mar 2023RevenueNet incomeNet losstallest bar $44.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$41.9M
30 Jun 2026–-$38.3M
31 Mar 2026–-$39.7M
31 Dec 2025–-$37.8M
30 Sep 2025–-$36.8M
30 Jun 2025–-$42.1M
31 Mar 2025–-$44.6M
31 Dec 2024–-$37.5M
30 Sep 2024–-$34.5M
30 Jun 2024–-$28.8M
31 Mar 2024–-$26.7M
31 Dec 2023–-$20.7M
30 Sep 2023–-$15.5M
30 Jun 2023–-$13.1M
31 Mar 2023–-$11.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$157.8M -$161.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.76 -$3.73
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -111% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$157.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $170.6M $171.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $25.0M –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$145.6M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.19 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.11
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.0 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Kyverna TherapeuticsKYTX (this company) $269.3Mloss–––
AgenusAGEN $270.1M8.82.0+25%23.0%
OcugenOCGN $260.6Mloss54.5-11%–
Eikon TherapeuticsEIKN $256.8M––––
Precision BioSciencesDTIL $282.5Mloss6.3+6353%-85.6%
SAB BiotherapeuticsSABS $253.1Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+6.7%

127 13F filers vs 119

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

56%

35.2M shares held by 13F filers (30 Sep 2026) of 63.2M outstanding (6 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

14%

9.1M shares sold short (30 Oct 2026) of 63.2M outstanding (6 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

11.6

9.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-4.7%

9.5M shares sold short in the report before, 9.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

61%

61% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$370K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

17

17 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.2×

17 articles in the last 7 days; its usual week has 4.

Price $4.26 on 20 Nov 2026, -43% over 12 months (12-month range $4.26 to $11.25)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $707K in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months, +100% on the 12 months before.
Capital spending per quarter. Capital spending $174K in the latest quarter, +8600% on a year earlier.
Institutional holders (13F filers). 127 13F filers reported holding it in the latest 13F quarter, +74% on a year earlier.
Lobbying spend. Lobbying spend: $370K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
18 May 20268-K and other filingsDirector or officer change
3 Apr 2026Lobbying filingnew lobbying registration (BROWNSTEIN HYATT FARBER SCHRECK, LLP)
24 Feb 20268-K and other filingsDirector or officer change
3 Feb 20268-K and other filingsDirector or officer change
12 Jan 20268-K and other filingsDirector or officer change
12 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Oct 2025Lobbying filingnew lobbying registration (AKIN GUMP STRAUSS HAUER & FELD)
23 Oct 2025Sharp changeFirst lobbying registration: first lobbying registration: KYVERNA THERAPEUTICS, INC.: new lobbying registration (AKIN GUMP STRAUSS HAUER & FELD)
25 Sep 20258-K and other filingsDirector or officer change
30 Jun 20258-K and other filingsDirector or officer change
30 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Nov 20248-K and other filingsDirector or officer change
13 Nov 20248-K and other filingsDirector or officer change
21 Oct 20248-K and other filingsDirector or officer change
16 Sep 20248-K and other filingsDirector or officer change
16 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Feb 2024Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 45.4M)
6 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
1 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
16 Jan 20248-K and other filingsRegistered new securities for sale (S-1)
7 Nov 20238-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Feb 2024: $45.4M published
Month from 1 Dec 2025: $707K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 1 published
Capital spending per quarter
Quarter ended 31 Mar 2023: $28K; public on 15 May 2024
Quarter ended 30 Sep 2023: $256K; public on 14 Nov 2024
Quarter ended 31 Dec 2023: $334K; public on 28 Mar 2025
Quarter ended 31 Mar 2024: $543K, +1839% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $1.0M; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $102K, -60% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $532K, +59% on a year earlier; public on 28 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $4K, -100% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $2K, -98% on a year earlier; public on 13 Nov 2025
Quarter ended 30 Sep 2026: $174K, +8600% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Mar 2024 report: 86; public on 15 May 2024
30 Jun 2024 report: 85; public on 14 Aug 2024
30 Sep 2024 report: 91; public on 14 Nov 2024
31 Dec 2024 report: 84; public on 14 Feb 2025
31 Mar 2025 report: 84; public on 15 May 2025
30 Jun 2025 report: 75; public on 14 Aug 2025
30 Sep 2025 report: 73; public on 14 Nov 2025
31 Dec 2025 report: 97; public on 17 Feb 2026
31 Mar 2026 report: 109; public on 15 May 2026
30 Jun 2026 report: 119; public on 14 Aug 2026
30 Sep 2026 report: 127; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $120K published
Quarter from 1 Oct 2026: $120K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 127 (30 Sep 2026), 1.5× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $707K in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months, +100% on the 12 months before.
  • Capital spending per quarter: Capital spending $174K in the latest quarter, +8600% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 7 insider trades

No trades in the last 90 days; the latest was filed 22 Dec 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
22 Dec 2025Westlake BioPartners Opportunity Fund I, L.P. and 3 others10% ownerBuy133,333$7.50$1.0MForm 4
17 Dec 2025Karen Marie WalkerChief Technology OfficerSellplanned in advance (10b5-1); after exercising options23,998$12.20$293KForm 4
14 Feb 2024Vida Ventures GP III, L.L.C. and 3 others10% ownerBuy253,136$22.00$5.6MForm 4
14 Feb 2024Bain Capital Life Sciences Fund III, L.P. and 4 others10% ownerBuy450,000$22.00$9.9MForm 4
13 Feb 2024Gilead Sciences, Inc.10% ownerBuy910,000$22.00$20.0MForm 4
12 Feb 2024Northpond Ventures III GP, LLC and 2 othersFormer 10% OwnerBuy450,000$22.00$9.9MForm 4

127 institutions reported shares at the end of Q3 2026, 56% of the shares outstanding; 26 opened a position, 17 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
GordonMD Global Investments LP4.5M7.15%$30.7M+276K+6.5%
Gilead Sciences, Inc.4.1M6.53%$28.1MNo change
AIGH Capital Management LLC3.6M5.77%$24.8M+854K+31%
BlackRock, Inc.3.2M5.12%$22.0M+103K+3.3%
Vanguard Capital Management LLC2.0M3.18%$13.7M+114K+6.0%
Bain Capital Life Sciences Investors, LLC1.3M2.08%$8.9M-1.6M-55%
T. Rowe Price Associates Inc1.2M1.91%+22K+1.8%
State Street Corp1.2M1.90%$8.2M+221K+23%
Geode Capital Management, LLC1.1M1.67%$7.2M+4,251+0.4%
Insight Holdings Group, LLC989K1.56%$6.7MNo change

Company events

All 19 company events

In 12 months: 4 director or officer changes, 3 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
27 Jul 2026Signed a major agreement8-K
9 Jul 2026Signed a major agreement8-K
18 May 2026Director or officer change8-K
24 Feb 2026Director or officer change8-K
3 Feb 2026Director or officer change8-K
12 Jan 2026Director or officer change8-K
17 Dec 2025Signed a major agreement8-K
3 Nov 2025Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $120K in Q3 2026, $120K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Mar 2026NewBrownstein Hyatt Farber Schreck, LLPfor Kyverna Therapeutics, Inc.Outreach regarding cell therapies for autoimmune diseases.Health issuesFiling
10 Oct 2025NewAkin Gump Strauss Hauer & Feldfor Kyverna Therapeutics, Inc.Issues related to developing cell therapies for patients.Health issuesFiling

The 5 newest of 208 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 18 May 2026Filings record

    Director or officer change

  2. 3 Apr 2026Lobbying record

    KYVERNA THERAPEUTICS, INC.: new lobbying registration (BROWNSTEIN HYATT FARBER SCHRECK, LLP) (dated 1 Mar 2026)

  3. 24 Feb 2026Filings record

    Director or officer change

  4. 3 Feb 2026Filings record

    Director or officer change

  5. 12 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 12 Jan 2026Filings record

    Director or officer change

  7. 23 Dec 2025Insiders record

    SEIDENBERG BETH C (director) bought 133,333 shares of KYTX [same transaction as an earlier filing] (dated 22 Dec 2025)

  8. 23 Dec 2025Insiders record

    Westlake BioPartners Opportunity Fund I, L.P. (ten percent owner) and 3 other(s) bought 133,333 shares of KYTX ($999,998) (dated 22 Dec 2025)

  9. 23 Oct 2025Lobbying change

    registered for federal lobbying for the first time in our data (Akin Gump Strauss Hauer & Feld).

    See the evidence (1 source record)
    Source coverage starts
    4 Apr 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  10. 23 Oct 2025Lobbying record

    KYVERNA THERAPEUTICS, INC.: new lobbying registration (AKIN GUMP STRAUSS HAUER & FELD) (dated 10 Oct 2025)

  11. 25 Sep 2025Filings record

    Director or officer change

  12. 30 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 30 Jun 2025Filings record

    Director or officer change

  14. 26 Nov 2024Filings record

    Director or officer change

  15. 13 Nov 2024Filings record

    Director or officer change

  16. 21 Oct 2024Filings record

    Director or officer change

  17. 16 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 16 Sep 2024Filings record

    Director or officer change

  19. 15 Feb 2024Insiders change

    had 4 insiders buy $45.4M of its shares on the open market within 30 days (4 filings).

    Who bought: Gilead Sciences, Inc..

    See the evidence (4 source records)
    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $45.4M
    Window
    16 Jan 2024 to 15 Feb 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  20. 15 Feb 2024Insiders record

    Vida Ventures GP III, L.L.C. (ten percent owner) and 3 other(s) bought 253,136 shares of KYTX ($5.6M) (dated 14 Feb 2024)

  21. 15 Feb 2024Insiders record

    Bain Capital Life Sciences Fund III, L.P. (ten percent owner) and 4 other(s) bought 450,000 shares of KYTX ($9.9M) (dated 14 Feb 2024)

  22. 14 Feb 2024Insiders record

    GILEAD SCIENCES, INC. (ten percent owner) bought 910,000 shares of KYTX ($20.0M) (dated 13 Feb 2024)

  23. 13 Feb 2024Insiders record

    Northpond Ventures III GP, LLC (Former 10% Owner) and 2 other(s) bought 450,000 shares of KYTX ($9.9M) (dated 12 Feb 2024)

  24. 6 Feb 2024Filings record

    Registered new securities for sale (S-1)

  25. 1 Feb 2024Filings record

    Registered new securities for sale (S-1) (dated 31 Jan 2024)

  26. 16 Jan 2024Filings record

    Registered new securities for sale (S-1)

  27. 7 Nov 2023Filings record

    Private placement of securities (Form D) (dated 6 Nov 2023)

Not listed: 42 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001994702
Ticker
KYTX
Domain
kyvernatx.com
Employer name
Kyverna Therapeutics, Inc. (1 unverified)
Hq location
CA|EMERYVILLE| (1 unverified)
Lobbying client
kyverna therapeutics
Name
Kyverna Therapeutics, Inc.
  • DOL H-1B labor condition applications and PERM certifications27 data points17 May 2021 to 17 Aug 2026
  • Federal lobbying disclosures (LDA)2 records, 12 data points10 Oct 2025 to 30 Sep 2026
  • SEC Form 13F institutional holdings99 data points31 Mar 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)55 records6 Nov 2023 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)197 data points31 Dec 2022 to 6 Nov 2026
  • SEC Form 4 insider transactions7 records, 20 data points12 Feb 2024 to 22 Dec 2025
  • FINRA short interest (twice monthly)197 data points15 Feb 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1400 data points8 Feb 2024 to 20 Nov 2026